GSA Capital Partners LLP lowered its stake in shares of Incyte Corporation (NASDAQ:INCY) by 8.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,820 shares of the biopharmaceutical company’s stock after selling 2,468 shares during the period. GSA Capital Partners LLP’s holdings in Incyte Corporation were worth $3,503,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wetherby Asset Management Inc. raised its holdings in shares of Incyte Corporation by 1.4% during the second quarter. Wetherby Asset Management Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 23 shares during the period. Grandfield & Dodd LLC raised its holdings in shares of Incyte Corporation by 1.2% during the second quarter. Grandfield & Dodd LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $930,000 after purchasing an additional 85 shares during the period. IFP Advisors Inc raised its holdings in shares of Incyte Corporation by 9.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 103 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Incyte Corporation by 5.4% in the 2nd quarter. State of Alaska Department of Revenue now owns 2,292 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 117 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in shares of Incyte Corporation by 2.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 4,855 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 88.91% of the company’s stock.

Incyte Corporation (NASDAQ:INCY) traded down 0.88% on Tuesday, hitting $117.36. 574,018 shares of the stock were exchanged. The company has a 50-day moving average of $126.90 and a 200-day moving average of $130.06. The stock’s market cap is $24.14 billion. Incyte Corporation has a 12 month low of $83.01 and a 12 month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The company had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. During the same period in the previous year, the firm earned $0.18 earnings per share. The firm’s revenue for the quarter was up 32.5% on a year-over-year basis. On average, equities analysts predict that Incyte Corporation will post ($0.83) EPS for the current year.

In other news, EVP Barry P. Flannelly sold 714 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total transaction of $88,714.50. Following the completion of the transaction, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at $1,925,378. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David W. Gryska sold 599 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $129.74, for a total transaction of $77,714.26. Following the transaction, the insider now directly owns 19,614 shares of the company’s stock, valued at $2,544,720.36. The disclosure for this sale can be found here. Insiders have sold 44,369 shares of company stock valued at $5,971,609 over the last three months. 17.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/19/gsa-capital-partners-llp-reduces-stake-in-incyte-corporation-incy.html.

A number of research firms recently weighed in on INCY. Royal Bank Of Canada began coverage on shares of Incyte Corporation in a report on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 target price on the stock. Argus restated a “buy” rating and issued a $150.00 target price on shares of Incyte Corporation in a report on Wednesday, September 13th. Oppenheimer Holdings, Inc. restated a “hold” rating and issued a $135.00 target price on shares of Incyte Corporation in a report on Sunday, September 10th. BMO Capital Markets restated an “outperform” rating and issued a $163.00 target price (down previously from $172.00) on shares of Incyte Corporation in a report on Monday, September 11th. Finally, Raymond James Financial, Inc. upgraded shares of Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 target price on the stock in a report on Monday, September 11th. Eight research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Incyte Corporation has an average rating of “Buy” and an average target price of $142.16.

Incyte Corporation Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.